EGFR isoforms and gene regulation in human endometrial cancer cells
Open Access
- 25 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 9 (1), 166
- https://doi.org/10.1186/1476-4598-9-166
Abstract
Background: Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal growth-promoting pathway in endometrial cancer cells. Pre-clinical studies were undertaken to compare the expression of EGFR isoforms and the downstream effects of activating or blocking EGFR function in Ishikawa H cells, derived from a moderately differentiated type I endometrioid adenocarcinoma, or in Hec50co cells, derived from a poorly differentiated type II adenocarcinoma with papillary serous sub-differentiation. Results: We investigated whether EGFR mutations are present in the tyrosine kinase domain (exons 18-22) of EGFR and also whether EGFR isoforms are expressed in the Ishikawa H or Hec50co cell lines. Sequence of the EGFR tyrosine kinase domain proved to be wild type in both cell lines. While both cell lines expressed full-length EGFR (isoform A), EGFR and sEGFR (isoform D) were expressed at significantly lower levels in Hec50co cells compared to Ishikawa H cells. Analysis of gene expression following EGF vs. gefitinib treatment (a small molecule EGFR tyrosine kinase inhibitor) was performed. Early growth response 1, sphingosine kinase 2, dual specificity phosphatase 6, and glucocorticoid receptor DNA binding factor 1 are members of a cluster of genes downstream of EGFR that are differentially regulated by treatment with EGF compared to gefitinib in Ishikawa H cells, but not in Hec50co cells. Conclusions: Type I Ishikawa H and type II Hec50co endometrial carcinoma cells both express EGFR and sEGFR, but differ markedly in their responsiveness to the EGFR inhibitor gefitinib. This difference is paralleled by differences in the expression of sEGFR and EGFR, as well as in their transcriptional response following treatment with either EGF or gefitinib. The small cluster of differently regulated genes reported here in these type I vs. type II endometrial cancer-derived cell lines may identify candidate biomarkers useful for predicting sensitivity to EGFR blockade.Keywords
This publication has 42 references indexed in Scilit:
- Increased epithelial stem cell traits in advanced endometrial endometrioid carcinomaBMC Genomics, 2009
- RPS2: a novel therapeutic target in prostate cancerJournal of Experimental & Clinical Cancer Research, 2009
- HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancerBritish Journal of Cancer, 2008
- Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?Cancer Chemotherapy and Pharmacology, 2008
- Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel‐Lindau suppression and HIF1α activationInternational Journal of Cancer, 2006
- Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Generation and Characterization of Polyclonal Antibodies Specific for Human p110 sEGFRHybridoma and Hybridomics, 2002
- Monoclonal Antibodies Specific for Peptide Epitopes of the Epidermal Growth Factor Receptor's Extracellular DomainHybridoma, 1997